ImmunoGenesis

ImmunoGenesis is an immuno-oncology biopharmaceutical company re-envisioning “cold” tumor treatment. We are crafting sophisticated, science-driven immune therapies to transform cold tumors into hot tumors by targeting key mechanisms of immune resistance. Michael Curran founded ImmunoGenesis in 2019 around a unique PD-1 pathway—blocking antibody: IMGS-001, a dual-specific PD-L1/PD-L2 inhibitor and the first antibody known to target PD-L2. ImmunoGenesis has found its perfect launchpad in JLABS @ TMC, a “biotech incubator space” in Houston that provides state-of-the-art equipment and an atmosphere of innovation. ImmunoGenesis brings a clear and singular focus to the complex realm of cancer treatment. We are developing science-driven immunotherapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. We are approaching treatment for cold tumors through a new lens, re-envisioning treatment with a deliberate drug development strategy based in cold tumor pathology. This vision puts ImmunoGenesis at the forefront of scientific exploration.